From clinical trials to clawback reform, pharma leaders say Greece must move faster to attract investment under Europe’s new biotech strategy
The forthcoming EU Biotech Act is increasingly being viewed as more than another European health initiative. For many in the pharmaceutical industry, it marks a broader shift in EU thinking; from supporting innovation to competing globally for it.
That shift was also reflected in recent discussions during the “Innovation Meets Industry” initiative organised by the Hellenic Association of Pharmaceutical Companies (SFEE), which brought together policymakers, researchers, and industry representatives to discuss the future of pharmaceutical innovation in Greece.
The emerging message from industry leaders is that scientific excellence alone will no longer be enough. Countries will increasingly compete on speed, regulatory predictability, investment conditions and their ability to scale research into commercial activity.
And while executives agree Greece has important advantages, they also warn that the country risks falling behind unless long-standing structural weaknesses are addressed.
